首页 > 最新文献

Clinical breast cancer最新文献

英文 中文
Another Biosignature for Ductal Carcinoma In Situ-Have We Moved the Needle? 乳腺导管原位癌的另一个生物特征--我们移针了吗?
IF 2.9 3区 医学 Q2 ONCOLOGY Pub Date : 2024-10-30 DOI: 10.1016/j.clbc.2024.10.017
Hannah Bacon, Ezra Hahn
{"title":"Another Biosignature for Ductal Carcinoma In Situ-Have We Moved the Needle?","authors":"Hannah Bacon, Ezra Hahn","doi":"10.1016/j.clbc.2024.10.017","DOIUrl":"https://doi.org/10.1016/j.clbc.2024.10.017","url":null,"abstract":"","PeriodicalId":10197,"journal":{"name":"Clinical breast cancer","volume":" ","pages":""},"PeriodicalIF":2.9,"publicationDate":"2024-10-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142695220","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Association of Skeletal Muscle Mass and Muscle Quality at Diagnosis With Survival in Young Women With Breast Cancer: Retrospective Observational Study. 年轻女性乳腺癌患者确诊时骨骼肌质量和肌肉质量与生存期的关系:回顾性观察研究
IF 2.9 3区 医学 Q2 ONCOLOGY Pub Date : 2024-10-28 DOI: 10.1016/j.clbc.2024.10.014
Aynur Aktas, Rebecca Sheaff Greiner, Matthew Flores, Danielle Boselli, Taylor Stone, Eric Wang, Lejla Hadzikadic-Gusic, Michelle L Wallander, Anna Hecksher, Chasse Bailey-Dorton, Declan Walsh

Background: Low skeletal muscle mass and poor muscle quality are associated with poor outcomes in women with breast cancer. However, gaps exist in our understanding of prognostic factors for young women (≤ 40 years), as they often have different body composition than older women. We evaluated pretreatment body composition measures in young women with breast cancer, including associations with overall survival (OS) and progression-free survival (PFS).

Methods: The Young Women's Database at Levine Cancer Institute was queried for women aged 18 to 40 at diagnosis (2009-2018) of single primary breast cancer (N = 870); patients with Stage 0 and 4 were excluded. Deceased patients with pretreatment computed tomography (CT) scans were identified (N = 40) and matched (1:1) to patients presumed alive by age, diagnosis year, and disease characteristics. CT-derived body composition measures included skeletal muscle index (SMI) and intramuscular adipose tissue corrected (IMAT-C). Sarcopenia (low muscle mass) was defined as SMI<40.

Results: Of 80 subjects, median age at diagnosis was 35 years. Median follow-up 8.6 years. Total 33% had low muscle mass (sarcopenic), and 56% had poor muscle quality (high IMAT-C). Independent of age, clinical disease stage, and primary insurer, high IMAT-C was associated with shorter PFS (HR 2.33, 95% CI 1.15-4.72; P = .020).

Conclusions: Poor muscle quality at diagnosis was associated with shorter progression-free survival in young women with breast cancer. Future research should determine the significance of changes in muscle quality throughout treatment.

背景:骨骼肌质量低和肌肉质量差与乳腺癌妇女的不良预后有关。然而,我们对年轻女性(40 岁以下)预后因素的了解还存在差距,因为她们的身体成分通常与老年女性不同。我们评估了年轻女性乳腺癌患者治疗前的身体成分测量结果,包括与总生存期(OS)和无进展生存期(PFS)的关系:在莱文癌症研究所的年轻女性数据库中查询了年龄在18至40岁之间、诊断为单发原发性乳腺癌的女性(2009-2018年)(N = 870);排除了0期和4期患者。确定了有治疗前计算机断层扫描(CT)扫描结果的死亡患者(N = 40),并按年龄、诊断年份和疾病特征与推测存活的患者进行了配对(1:1)。计算机断层扫描得出的身体成分测量值包括骨骼肌指数(SMI)和肌肉内脂肪组织校正值(IMAT-C)。肌肉疏松症(肌肉质量低)定义为 SMIResults:在 80 名受试者中,诊断时的中位年龄为 35 岁。中位随访时间为 8.6 年。共有 33% 的受试者肌肉质量低(肌肉疏松症),56% 的受试者肌肉质量差(IMAT-C 高)。与年龄、临床疾病分期和原发性保险公司无关,高IMAT-C与较短的PFS相关(HR 2.33,95% CI 1.15-4.72;P = .020):结论:诊断时肌肉质量差与年轻女性乳腺癌患者无进展生存期缩短有关。未来的研究应确定在整个治疗过程中肌肉质量变化的意义。
{"title":"Association of Skeletal Muscle Mass and Muscle Quality at Diagnosis With Survival in Young Women With Breast Cancer: Retrospective Observational Study.","authors":"Aynur Aktas, Rebecca Sheaff Greiner, Matthew Flores, Danielle Boselli, Taylor Stone, Eric Wang, Lejla Hadzikadic-Gusic, Michelle L Wallander, Anna Hecksher, Chasse Bailey-Dorton, Declan Walsh","doi":"10.1016/j.clbc.2024.10.014","DOIUrl":"https://doi.org/10.1016/j.clbc.2024.10.014","url":null,"abstract":"<p><strong>Background: </strong>Low skeletal muscle mass and poor muscle quality are associated with poor outcomes in women with breast cancer. However, gaps exist in our understanding of prognostic factors for young women (≤ 40 years), as they often have different body composition than older women. We evaluated pretreatment body composition measures in young women with breast cancer, including associations with overall survival (OS) and progression-free survival (PFS).</p><p><strong>Methods: </strong>The Young Women's Database at Levine Cancer Institute was queried for women aged 18 to 40 at diagnosis (2009-2018) of single primary breast cancer (N = 870); patients with Stage 0 and 4 were excluded. Deceased patients with pretreatment computed tomography (CT) scans were identified (N = 40) and matched (1:1) to patients presumed alive by age, diagnosis year, and disease characteristics. CT-derived body composition measures included skeletal muscle index (SMI) and intramuscular adipose tissue corrected (IMAT-C). Sarcopenia (low muscle mass) was defined as SMI<40.</p><p><strong>Results: </strong>Of 80 subjects, median age at diagnosis was 35 years. Median follow-up 8.6 years. Total 33% had low muscle mass (sarcopenic), and 56% had poor muscle quality (high IMAT-C). Independent of age, clinical disease stage, and primary insurer, high IMAT-C was associated with shorter PFS (HR 2.33, 95% CI 1.15-4.72; P = .020).</p><p><strong>Conclusions: </strong>Poor muscle quality at diagnosis was associated with shorter progression-free survival in young women with breast cancer. Future research should determine the significance of changes in muscle quality throughout treatment.</p>","PeriodicalId":10197,"journal":{"name":"Clinical breast cancer","volume":" ","pages":""},"PeriodicalIF":2.9,"publicationDate":"2024-10-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142692560","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Development and Validation of a Novel Conditional Survival Nomogram for Predicting Real-Time Prognosis in Patients With Breast Cancer Brain Metastasis. 开发并验证用于预测乳腺癌脑转移患者实时预后的新型条件生存提名图
IF 2.9 3区 医学 Q2 ONCOLOGY Pub Date : 2024-10-28 DOI: 10.1016/j.clbc.2024.10.016
Yongqing Zhang, Mingjie Zhang, Guoxiu Yu, Wenhui Wang

Background: Breast cancer brain metastasis (BCBM) prognosis has not been evaluated dynamically, which may underestimate patient survival. This study aimed to perform a conditional survival (CS) analysis and develop and validate an individualized real-time prognostic monitoring model for survivors.

Methods: The study included patients with BCBM from the Surveillance, Epidemiology, and End Results database (training group, n = 998) and our institution (validation group, n = 45) and updated patient overall survival (OS) over time using the CS method: CS(t2|t1)=OS(t1+t2)OS(t1). Multivariate Cox regression was used to identify prognostic factors for the nomogram, which estimated individualized OS. Furthermore, a novel CS-nomogram and its web version were further developed based on the CS formula.

Results: CS analysis showed that the 5-year OS of BCBM survivors gradually improved from 13.5% estimated at diagnosis to 26.0%, 39.7%, 57.9%, and 77.6% (surviving 1-4 years, respectively). Cox regression identified age, marital status, estrogen receptor status, human epidermal growth factor receptor 2 (Her-2) status, histological grade, surgery, and chemotherapy as significant factors influencing OS (P < .05). We then constructed and deployed the CS-nomogram based on the CS formula and the nomogram to predict real-time prognosis dynamically (https://wh-wang.shinyapps.io/BCBM/). During performance evaluation, the model performed well in both the training and validation groups.

Conclusions: CS analysis showed a gradual improvement in prognosis over time for BCBM survivors. We developed and deployed on the web a novel real-time dynamic prognostic monitoring system, the CS-nomogram, which provided valuable survival data for clinical decision-making, patient counseling, and optimal allocation of healthcare resources.

背景:乳腺癌脑转移(BCBM)的预后尚未得到动态评估,这可能会低估患者的生存率。本研究旨在进行条件生存(CS)分析,并开发和验证针对幸存者的个性化实时预后监测模型:研究纳入了来自监测、流行病学和最终结果数据库(训练组,n = 998)和本机构(验证组,n = 45)的 BCBM 患者,并使用 CS 方法更新了患者随时间推移的总生存期(OS):CS(t2|t1)=OS(t1+t2)OS(t1)。多变量 Cox 回归用于确定提名图的预后因素,从而估算出个体化的 OS。此外,在CS公式的基础上进一步开发了新的CS提名图及其网络版:CS分析显示,BCBM幸存者的5年OS从诊断时估计的13.5%逐渐提高到26.0%、39.7%、57.9%和77.6%(分别存活1-4年)。Cox回归发现,年龄、婚姻状况、雌激素受体状态、人表皮生长因子受体2(Her-2)状态、组织学分级、手术和化疗是影响OS的重要因素(P < .05)。然后,我们根据CS公式和提名图构建并部署了CS-提名图,以动态预测实时预后(https://wh-wang.shinyapps.io/BCBM/)。在性能评估过程中,该模型在训练组和验证组均表现良好:CS分析表明,随着时间的推移,BCBM幸存者的预后会逐渐改善。我们在网络上开发并部署了一个新颖的实时动态预后监测系统--CS-nomogram,它为临床决策、患者咨询和医疗资源的优化配置提供了宝贵的生存数据。
{"title":"Development and Validation of a Novel Conditional Survival Nomogram for Predicting Real-Time Prognosis in Patients With Breast Cancer Brain Metastasis.","authors":"Yongqing Zhang, Mingjie Zhang, Guoxiu Yu, Wenhui Wang","doi":"10.1016/j.clbc.2024.10.016","DOIUrl":"https://doi.org/10.1016/j.clbc.2024.10.016","url":null,"abstract":"<p><strong>Background: </strong>Breast cancer brain metastasis (BCBM) prognosis has not been evaluated dynamically, which may underestimate patient survival. This study aimed to perform a conditional survival (CS) analysis and develop and validate an individualized real-time prognostic monitoring model for survivors.</p><p><strong>Methods: </strong>The study included patients with BCBM from the Surveillance, Epidemiology, and End Results database (training group, n = 998) and our institution (validation group, n = 45) and updated patient overall survival (OS) over time using the CS method: CS(t2|t1)=OS(t1+t2)OS(t1). Multivariate Cox regression was used to identify prognostic factors for the nomogram, which estimated individualized OS. Furthermore, a novel CS-nomogram and its web version were further developed based on the CS formula.</p><p><strong>Results: </strong>CS analysis showed that the 5-year OS of BCBM survivors gradually improved from 13.5% estimated at diagnosis to 26.0%, 39.7%, 57.9%, and 77.6% (surviving 1-4 years, respectively). Cox regression identified age, marital status, estrogen receptor status, human epidermal growth factor receptor 2 (Her-2) status, histological grade, surgery, and chemotherapy as significant factors influencing OS (P < .05). We then constructed and deployed the CS-nomogram based on the CS formula and the nomogram to predict real-time prognosis dynamically (https://wh-wang.shinyapps.io/BCBM/). During performance evaluation, the model performed well in both the training and validation groups.</p><p><strong>Conclusions: </strong>CS analysis showed a gradual improvement in prognosis over time for BCBM survivors. We developed and deployed on the web a novel real-time dynamic prognostic monitoring system, the CS-nomogram, which provided valuable survival data for clinical decision-making, patient counseling, and optimal allocation of healthcare resources.</p>","PeriodicalId":10197,"journal":{"name":"Clinical breast cancer","volume":" ","pages":""},"PeriodicalIF":2.9,"publicationDate":"2024-10-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142680997","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Transforming Breast Cancer Care and Clinical Outcomes: Local Experience in Yanbu Industrial City, Saudi Arabia. 转变乳腺癌护理和临床结果:沙特阿拉伯延布工业城的当地经验。
IF 2.9 3区 医学 Q2 ONCOLOGY Pub Date : 2024-10-26 DOI: 10.1016/j.clbc.2024.10.011
Hend Samir Ibrahim, Salman M Albeshan, Manal Ahmed ElRefaei

Objective: This study aimed to enhance outcomes for women undergoing breast cancer screening in a low utilization setting by implementing structured improvement cycles.

Methods: Improvement cycles were conducted using the Plan-Do-Study-Act (PDSA) methodology. Three cycles were implemented: (1) dedicating a specific day for breast screening and increasing appointment slots; (2) establishing a breast screening clinic with same-day registration; and (3) introducing a breast surgery clinic to expedite biopsy procedures for BI-RADS-4 category cases.

Results: Following each improvement cycle, dramatic increases in patient attendance were observed. In 2021, there was a 67.5% rise compared to the previous year, and a 72% increase in 2022 compared to 2021 figures. Patient characteristics revealed that 60% of attendees were new patients, with 53% of cancer and precancerous cases observed in women below 50 years old. Before the third cycle, the estimated diagnosis turnaround time (TAT) showed that only 23% of patients had their biopsy completed within 5 working days. However, after the third cycle (n = 131), 63.5% of biopsies were done within five working days.

Conclusion: Structured improvement cycles guided by the PDSA methodology effectively enhanced breast cancer screening outcomes. These cycles led to increased patient attendance, expedited biopsy procedures, and improved access to timely diagnosis. The findings highlight the importance of systematic approaches in optimizing breast cancer screening and improving patient care.

目的本研究旨在通过实施结构化的改进周期,提高低利用率环境中接受乳腺癌筛查的妇女的治疗效果:方法:采用 "计划-实施-研究-行动"(Plan-Do-Study-Act,PDSA)方法实施改进周期。共实施了三个周期:(1)指定一天进行乳腺癌筛查并增加预约名额;(2)设立乳腺癌筛查门诊,提供当天登记服务;以及(3)引入乳腺外科门诊,加快 BI-RADS-4 类病例的活检程序:结果:每个改进周期结束后,患者就诊率都有显著提高。2021 年比上一年增加了 67.5%,2022 年比 2021 年增加了 72%。患者特征显示,60%的就诊者是新患者,53%的癌症和癌前病例发生在 50 岁以下的女性身上。在第三个周期之前,估计的诊断周转时间(TAT)显示,只有 23% 的患者能在 5 个工作日内完成活检。然而,在第三个周期后(n = 131),63.5%的活检在 5 个工作日内完成:结论:以 PDSA 方法为指导的结构化改进周期有效提高了乳腺癌筛查的效果。这些周期提高了患者就诊率,加快了活检程序,改善了及时诊断的机会。研究结果凸显了系统化方法在优化乳腺癌筛查和改善患者护理方面的重要性。
{"title":"Transforming Breast Cancer Care and Clinical Outcomes: Local Experience in Yanbu Industrial City, Saudi Arabia.","authors":"Hend Samir Ibrahim, Salman M Albeshan, Manal Ahmed ElRefaei","doi":"10.1016/j.clbc.2024.10.011","DOIUrl":"https://doi.org/10.1016/j.clbc.2024.10.011","url":null,"abstract":"<p><strong>Objective: </strong>This study aimed to enhance outcomes for women undergoing breast cancer screening in a low utilization setting by implementing structured improvement cycles.</p><p><strong>Methods: </strong>Improvement cycles were conducted using the Plan-Do-Study-Act (PDSA) methodology. Three cycles were implemented: (1) dedicating a specific day for breast screening and increasing appointment slots; (2) establishing a breast screening clinic with same-day registration; and (3) introducing a breast surgery clinic to expedite biopsy procedures for BI-RADS-4 category cases.</p><p><strong>Results: </strong>Following each improvement cycle, dramatic increases in patient attendance were observed. In 2021, there was a 67.5% rise compared to the previous year, and a 72% increase in 2022 compared to 2021 figures. Patient characteristics revealed that 60% of attendees were new patients, with 53% of cancer and precancerous cases observed in women below 50 years old. Before the third cycle, the estimated diagnosis turnaround time (TAT) showed that only 23% of patients had their biopsy completed within 5 working days. However, after the third cycle (n = 131), 63.5% of biopsies were done within five working days.</p><p><strong>Conclusion: </strong>Structured improvement cycles guided by the PDSA methodology effectively enhanced breast cancer screening outcomes. These cycles led to increased patient attendance, expedited biopsy procedures, and improved access to timely diagnosis. The findings highlight the importance of systematic approaches in optimizing breast cancer screening and improving patient care.</p>","PeriodicalId":10197,"journal":{"name":"Clinical breast cancer","volume":" ","pages":""},"PeriodicalIF":2.9,"publicationDate":"2024-10-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142681003","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Letter to the Editor Regarding the Article "The Impact of COVID-19 on Breast Cancer Care: A Qualitative Analysis of Surgeons' Perspectives". 致编辑的信,内容涉及 "COVID-19 对乳腺癌治疗的影响:外科医生观点的定性分析 "一文的来信。
IF 2.9 3区 医学 Q2 ONCOLOGY Pub Date : 2024-10-24 DOI: 10.1016/j.clbc.2024.10.015
Akshaya Viswanathan, Pitchaipillai Sankar Ganesh, Naji Naseef Pathoor, Rajesh Kanna Gopal

The COVID-19 pandemic exposed significant challenges in breast cancer care including healthcare inequities, limited access to surgeries, and difficulties in delivering virtual care. This letter builds upon the findings from the article "The Impact of COVID-19 on Breast Cancer Care" and proposes innovative solutions to address these challenges. Key suggestions include the use of AI-powered digital platforms for remote monitoring, robotic-assisted surgery for enhanced precision, mobile health applications for marginalized populations, and 3D printing for personalized breast reconstruction. Additionally, wearable health devices, nanotechnology for targeted drug delivery, and blockchain for secure medical data sharing are proposed to further improve the future of breast cancer care. These innovations offer practical approaches to overcoming the obstacles highlighted during the pandemic and aim to create a more equitable and efficient healthcare system.

COVID-19 大流行暴露了乳腺癌护理面临的重大挑战,包括医疗保健不公平、手术机会有限以及提供虚拟护理的困难。这封信以《COVID-19 对乳腺癌护理的影响》一文的研究结果为基础,提出了应对这些挑战的创新解决方案。主要建议包括使用人工智能驱动的数字平台进行远程监控、使用机器人辅助手术提高精准度、为边缘化人群提供移动医疗应用,以及使用 3D 打印技术进行个性化乳房重建。此外,还提出了可穿戴健康设备、用于靶向给药的纳米技术以及用于安全医疗数据共享的区块链,以进一步改善乳腺癌护理的未来。这些创新提供了切实可行的方法,以克服大流行病期间凸显的障碍,并旨在创建一个更加公平和高效的医疗保健系统。
{"title":"Letter to the Editor Regarding the Article \"The Impact of COVID-19 on Breast Cancer Care: A Qualitative Analysis of Surgeons' Perspectives\".","authors":"Akshaya Viswanathan, Pitchaipillai Sankar Ganesh, Naji Naseef Pathoor, Rajesh Kanna Gopal","doi":"10.1016/j.clbc.2024.10.015","DOIUrl":"https://doi.org/10.1016/j.clbc.2024.10.015","url":null,"abstract":"<p><p>The COVID-19 pandemic exposed significant challenges in breast cancer care including healthcare inequities, limited access to surgeries, and difficulties in delivering virtual care. This letter builds upon the findings from the article \"The Impact of COVID-19 on Breast Cancer Care\" and proposes innovative solutions to address these challenges. Key suggestions include the use of AI-powered digital platforms for remote monitoring, robotic-assisted surgery for enhanced precision, mobile health applications for marginalized populations, and 3D printing for personalized breast reconstruction. Additionally, wearable health devices, nanotechnology for targeted drug delivery, and blockchain for secure medical data sharing are proposed to further improve the future of breast cancer care. These innovations offer practical approaches to overcoming the obstacles highlighted during the pandemic and aim to create a more equitable and efficient healthcare system.</p>","PeriodicalId":10197,"journal":{"name":"Clinical breast cancer","volume":" ","pages":""},"PeriodicalIF":2.9,"publicationDate":"2024-10-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142647040","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Nonpharmacological Interventions for Postmastectomy Pain Syndrome-A Systematic Review of the Literature. 乳房切除术后疼痛综合征的非药物干预--文献系统性回顾。
IF 2.9 3区 医学 Q2 ONCOLOGY Pub Date : 2024-10-23 DOI: 10.1016/j.clbc.2024.10.007
Edmundo Gónima Valero, Cristian D Rodríguez Miranda, Sandra Contreras Arrieta, Maria I Daza Morelli, Daniela Seija Butnaru, Mariana Reyes Carrillo, Laura D Aponte Camacho, Sebastian Amaya

Objective: Literature regarding nonpharmacological interventions (NPI) for PMPS or CP after mastectomy is scarce and not fully appraised, therefore we conducted this systematic review to explore the current panorama of treatment options.

Methods: A systematic review to assess the existing evidence regarding nonpharmacological approaches for PMPS. We reviewed the following databases: PubMed-MEDLINE, Embase, and Ovid (including the Cochrane Database for Clinical studies) using the following search terms: CP, mastectomy, and PMPS, and adjusted the terms depending on the database used. We included observational studies including case reports, cross sectional studies, cohort studies, and clinical trials (randomized or not) that included a NPI to treat PMPS.

Results: Total 1061 records were identified. After duplicate elimination, 863 records were screened for eligibility. A total of 717 records were excluded using our criteria, 138 records were sought for retrieval, and 117 full text records were assessed. Finally, 30 studies were included: seven case series, one cross-sectional study, two cohort studies, one case-control study, five nonrandomized clinical trials, ten randomized clinical trials (RCT), one qualitative study, and three systematic reviews of the literature, including two meta analyses, were included.

Discussion: Findings suggest that there is a great response of patients to some NPI. Regarding surgical interventions, autologous fat grafting and lymph node transplantation showed to have the greatest benefit for patients in terms of quality of life and reduced pain scores. Pulsed radiofrequency demonstrated the highest quality of evidence for energy related procedures. Within the physical therapy interventions, transcutaneous electric nerve stimulation and dry needling showed the greatest benefit. Finally, virtual reality demonstrated the greatest benefit in educational interventions.

目的:有关乳房切除术后PMPS或CP的非药物干预(NPI)的文献很少,且未得到充分评估,因此我们进行了此次系统性综述,以探索当前治疗方案的全景:方法:进行系统性综述,评估有关治疗 PMPS 的非药物疗法的现有证据。我们查阅了以下数据库:PubMed-MEDLINE、Embase 和 Ovid(包括 Cochrane 临床研究数据库),并使用以下检索词:CP、乳房切除术和 PMPS,并根据所使用的数据库对术语进行了调整。我们纳入了包括病例报告在内的观察性研究、横断面研究、队列研究以及包含治疗 PMPS 的 NPI 的临床试验(随机或非随机):结果:共发现 1061 条记录。在剔除重复记录后,筛选出 863 条符合条件的记录。根据我们的标准,共排除了 717 条记录,检索了 138 条记录,评估了 117 条全文记录。最后,共纳入 30 项研究:7 项病例系列研究、1 项横断面研究、2 项队列研究、1 项病例对照研究、5 项非随机临床试验、10 项随机临床试验 (RCT)、1 项定性研究和 3 项系统性文献综述(包括 2 项元分析):讨论:研究结果表明,患者对某些 NPI 有很大的反应。在手术干预方面,自体脂肪移植和淋巴结移植在提高生活质量和降低疼痛评分方面对患者的益处最大。脉冲射频在能量相关程序方面的证据质量最高。在物理治疗干预中,经皮神经电刺激和干针疗法显示出最大的益处。最后,虚拟现实在教育干预方面显示出最大的益处。
{"title":"Nonpharmacological Interventions for Postmastectomy Pain Syndrome-A Systematic Review of the Literature.","authors":"Edmundo Gónima Valero, Cristian D Rodríguez Miranda, Sandra Contreras Arrieta, Maria I Daza Morelli, Daniela Seija Butnaru, Mariana Reyes Carrillo, Laura D Aponte Camacho, Sebastian Amaya","doi":"10.1016/j.clbc.2024.10.007","DOIUrl":"https://doi.org/10.1016/j.clbc.2024.10.007","url":null,"abstract":"<p><strong>Objective: </strong>Literature regarding nonpharmacological interventions (NPI) for PMPS or CP after mastectomy is scarce and not fully appraised, therefore we conducted this systematic review to explore the current panorama of treatment options.</p><p><strong>Methods: </strong>A systematic review to assess the existing evidence regarding nonpharmacological approaches for PMPS. We reviewed the following databases: PubMed-MEDLINE, Embase, and Ovid (including the Cochrane Database for Clinical studies) using the following search terms: CP, mastectomy, and PMPS, and adjusted the terms depending on the database used. We included observational studies including case reports, cross sectional studies, cohort studies, and clinical trials (randomized or not) that included a NPI to treat PMPS.</p><p><strong>Results: </strong>Total 1061 records were identified. After duplicate elimination, 863 records were screened for eligibility. A total of 717 records were excluded using our criteria, 138 records were sought for retrieval, and 117 full text records were assessed. Finally, 30 studies were included: seven case series, one cross-sectional study, two cohort studies, one case-control study, five nonrandomized clinical trials, ten randomized clinical trials (RCT), one qualitative study, and three systematic reviews of the literature, including two meta analyses, were included.</p><p><strong>Discussion: </strong>Findings suggest that there is a great response of patients to some NPI. Regarding surgical interventions, autologous fat grafting and lymph node transplantation showed to have the greatest benefit for patients in terms of quality of life and reduced pain scores. Pulsed radiofrequency demonstrated the highest quality of evidence for energy related procedures. Within the physical therapy interventions, transcutaneous electric nerve stimulation and dry needling showed the greatest benefit. Finally, virtual reality demonstrated the greatest benefit in educational interventions.</p>","PeriodicalId":10197,"journal":{"name":"Clinical breast cancer","volume":" ","pages":""},"PeriodicalIF":2.9,"publicationDate":"2024-10-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142675231","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Deubiquitinase OTUD7B Regulates Cell Proliferation in Breast Cancer. 去泛素酶 OTUD7B 调控乳腺癌细胞增殖
IF 2.9 3区 医学 Q2 ONCOLOGY Pub Date : 2024-10-22 DOI: 10.1016/j.clbc.2024.10.002
Xiu Zhang, Peng Zhang, Xiang Chen, Xianyi Liu, Wenwen Liu, Xi Hu, Chengcheng Sun, Xiaochun Wang, Jianhong Shi

Purpose: The deubiquitylase OTUD7B plays a facilitates role in lung tumorigenesis through VEGF protein, but its role in breast cancer remains unclear. In the present study, we proposed to explore the role of deubiquitylase OTUD7B in breast cancer.

Methods: The expression of OTUD7B in breast cancer and adjacent tissues was detected. The role of OTUD7B in cell proliferation and invasion of breast cancer cell lines such as MCF-7 and MDA-MB-453 was explored.

Results: OTUD7B is highly expressed in human breast cancer tissues and its higher expression correlates with better survival of patients. Further mechanistic studies reveal that OTUD7B associates with RASGRF1 and PLCE1 to disrupt RAS signaling pathway. Knockdown of OTUD7B results in decreasing levels of RASGRF1 protein, suppression cell growth and invasion in breast cancer. Collectively, our results reveal a previously unappreciated anti-oncogentic role OTUD7B involved in RAS signaling pathway in breast cancer and indicate that deubiquitylases could induce tumor-suppressing or tumor-promoting activities in a cell- and tissue-dependent context.

目的:去泛素化酶OTUD7B通过VEGF蛋白在肺部肿瘤发生中起促进作用,但其在乳腺癌中的作用尚不清楚。本研究拟探讨去泛素化酶 OTUD7B 在乳腺癌中的作用:方法:检测 OTUD7B 在乳腺癌及邻近组织中的表达。方法:检测 OTUD7B 在乳腺癌及邻近组织中的表达,探讨 OTUD7B 在 MCF-7 和 MDA-MB-453 等乳腺癌细胞系的细胞增殖和侵袭中的作用:结果:OTUD7B 在人类乳腺癌组织中高表达,其较高的表达与患者较好的生存率相关。进一步的机理研究发现,OTUD7B 与 RASGRF1 和 PLCE1 相关联,从而破坏 RAS 信号通路。敲除 OTUD7B 会降低 RASGRF1 蛋白水平,抑制乳腺癌细胞的生长和侵袭。总之,我们的研究结果揭示了 OTUD7B 在乳腺癌 RAS 信号通路中发挥的一种以前未被认识到的抗共轭作用,并表明去泛素化酶可在细胞和组织依赖性的背景下诱导肿瘤抑制或肿瘤促进活性。
{"title":"Deubiquitinase OTUD7B Regulates Cell Proliferation in Breast Cancer.","authors":"Xiu Zhang, Peng Zhang, Xiang Chen, Xianyi Liu, Wenwen Liu, Xi Hu, Chengcheng Sun, Xiaochun Wang, Jianhong Shi","doi":"10.1016/j.clbc.2024.10.002","DOIUrl":"https://doi.org/10.1016/j.clbc.2024.10.002","url":null,"abstract":"<p><strong>Purpose: </strong>The deubiquitylase OTUD7B plays a facilitates role in lung tumorigenesis through VEGF protein, but its role in breast cancer remains unclear. In the present study, we proposed to explore the role of deubiquitylase OTUD7B in breast cancer.</p><p><strong>Methods: </strong>The expression of OTUD7B in breast cancer and adjacent tissues was detected. The role of OTUD7B in cell proliferation and invasion of breast cancer cell lines such as MCF-7 and MDA-MB-453 was explored.</p><p><strong>Results: </strong>OTUD7B is highly expressed in human breast cancer tissues and its higher expression correlates with better survival of patients. Further mechanistic studies reveal that OTUD7B associates with RASGRF1 and PLCE1 to disrupt RAS signaling pathway. Knockdown of OTUD7B results in decreasing levels of RASGRF1 protein, suppression cell growth and invasion in breast cancer. Collectively, our results reveal a previously unappreciated anti-oncogentic role OTUD7B involved in RAS signaling pathway in breast cancer and indicate that deubiquitylases could induce tumor-suppressing or tumor-promoting activities in a cell- and tissue-dependent context.</p>","PeriodicalId":10197,"journal":{"name":"Clinical breast cancer","volume":" ","pages":""},"PeriodicalIF":2.9,"publicationDate":"2024-10-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142709589","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Real World Evidence Study to Assess Incidence, Treatment Patterns, Clinical Outcomes, and Health Care Resource Utilization in Early-Stage, High-Risk HER2-Negative Breast Cancer in Alberta, Canada. 真实世界证据研究:评估加拿大艾伯塔省早期高风险 HER2 阴性乳腺癌的发病率、治疗模式、临床结果和医疗资源利用情况。
IF 2.9 3区 医学 Q2 ONCOLOGY Pub Date : 2024-10-18 DOI: 10.1016/j.clbc.2024.10.008
Jan-Willem Henning, Devon J Boyne, Darren R Brenner, Chantelle Carbonell, Simran Shokar, Diana P Granados, Anna Parackal, Winson Y Cheung

Background: Data are needed to improve the current understanding of the epidemiology of patients with high-risk, HER2-negative, early breast cancer (eBC) (hormone receptor positive [HR+]/HER2-negative BC and triple-negative BC [TNBC]).

Patients and methods: This retrospective longitudinal cohort study used real-world, population-level data that included all individuals newly diagnosed with high-risk, HER2-negative eBC in Alberta, Canada, between 2010 and 2019. Data on treatment, laboratory results and pathology findings were collected through electronic health records and administrative databases.

Results: The annual cumulative incidence of high-risk, HER2-negative eBC ranged from 6% to 9% of all incident BC cases. Individuals with TNBC were more likely to be younger, had stage II disease, grade 3 histology and received systemic therapy at a community centre (P < .05) compared to individuals with HR+/HER2-negative eBC. Only 14% of individuals diagnosed in 2010-2017 underwent germline BRCA testing postdiagnosis. Neoadjuvant systemic therapy was given to 37% of individuals. Adjuvant systemic therapy use increased from 77% (2012-2015) to 84% (2019). The 5-year overall survival (OS) from initiation of adjuvant systemic therapy or date of surgery (for individuals who did not receive adjuvant systemic therapy) was 77% (95% CI: 75-79). OS was significantly worse among individuals who were older, had grade 3 histology, had stage III disease, or had nodal involvement (P < .05). OS among individuals with TNBC between 2016 and 2019 who initiated adjuvant capecitabine was markedly worse compared to the overall cohort (2-year OS: 70% vs. 89%).

Conclusion: Outcomes analyses in this high-risk, HER2-negative eBC population suggest a continued unmet clinical need.

背景:需要数据来提高目前对高风险、HER2 阴性、早期乳腺癌(eBC)(激素受体阳性[HR+]/HER2 阴性 BC 和三阴性 BC [TNBC])患者流行病学的了解:这项回顾性纵向队列研究使用了真实世界的人群水平数据,包括2010年至2019年期间加拿大艾伯塔省新诊断出的所有高危、HER2阴性eBC患者。有关治疗、实验室结果和病理结果的数据是通过电子健康记录和行政数据库收集的:高风险、HER2 阴性 eBC 的年累计发病率占 BC 病例总数的 6% 至 9%。与HR+/HER2阴性eBC患者相比,TNBC患者更有可能更年轻、患有II期疾病、组织学分级为3级且在社区中心接受过系统治疗(P < .05)。在2010-2017年期间确诊的患者中,只有14%在确诊后接受了种系BRCA检测。37%的患者接受了新辅助系统治疗。辅助系统疗法的使用率从77%(2012-2015年)增至84%(2019年)。从开始辅助系统治疗或手术日期(未接受辅助系统治疗者)算起的5年总生存率(OS)为77%(95% CI:75-79)。年龄较大、组织学分级为3级、疾病为III期或有结节受累的患者的OS明显较差(P < .05)。与整体队列相比,2016年至2019年期间罹患TNBC并开始卡培他滨辅助治疗的患者的OS明显较差(2年OS:70% vs. 89%):对这一高风险、HER2阴性eBC人群的结果分析表明,临床需求仍未得到满足。
{"title":"Real World Evidence Study to Assess Incidence, Treatment Patterns, Clinical Outcomes, and Health Care Resource Utilization in Early-Stage, High-Risk HER2-Negative Breast Cancer in Alberta, Canada.","authors":"Jan-Willem Henning, Devon J Boyne, Darren R Brenner, Chantelle Carbonell, Simran Shokar, Diana P Granados, Anna Parackal, Winson Y Cheung","doi":"10.1016/j.clbc.2024.10.008","DOIUrl":"https://doi.org/10.1016/j.clbc.2024.10.008","url":null,"abstract":"<p><strong>Background: </strong>Data are needed to improve the current understanding of the epidemiology of patients with high-risk, HER2-negative, early breast cancer (eBC) (hormone receptor positive [HR+]/HER2-negative BC and triple-negative BC [TNBC]).</p><p><strong>Patients and methods: </strong>This retrospective longitudinal cohort study used real-world, population-level data that included all individuals newly diagnosed with high-risk, HER2-negative eBC in Alberta, Canada, between 2010 and 2019. Data on treatment, laboratory results and pathology findings were collected through electronic health records and administrative databases.</p><p><strong>Results: </strong>The annual cumulative incidence of high-risk, HER2-negative eBC ranged from 6% to 9% of all incident BC cases. Individuals with TNBC were more likely to be younger, had stage II disease, grade 3 histology and received systemic therapy at a community centre (P < .05) compared to individuals with HR+/HER2-negative eBC. Only 14% of individuals diagnosed in 2010-2017 underwent germline BRCA testing postdiagnosis. Neoadjuvant systemic therapy was given to 37% of individuals. Adjuvant systemic therapy use increased from 77% (2012-2015) to 84% (2019). The 5-year overall survival (OS) from initiation of adjuvant systemic therapy or date of surgery (for individuals who did not receive adjuvant systemic therapy) was 77% (95% CI: 75-79). OS was significantly worse among individuals who were older, had grade 3 histology, had stage III disease, or had nodal involvement (P < .05). OS among individuals with TNBC between 2016 and 2019 who initiated adjuvant capecitabine was markedly worse compared to the overall cohort (2-year OS: 70% vs. 89%).</p><p><strong>Conclusion: </strong>Outcomes analyses in this high-risk, HER2-negative eBC population suggest a continued unmet clinical need.</p>","PeriodicalId":10197,"journal":{"name":"Clinical breast cancer","volume":" ","pages":""},"PeriodicalIF":2.9,"publicationDate":"2024-10-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142638528","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Assessing and Comparing the Diagnostic Effectiveness of [18F]FDG PET/CT and [18F]FDG PET/MRI for Distant Metastases in Breast Cancer Patients With Invasive Lobular Carcinoma Histology: An Ongoing Topic of Debate? 评估和比较[18F]FDG PET/CT和[18F]FDG PET/MRI对乳腺癌浸润性分叶状癌组织学远处转移的诊断效果:争论不休的话题?
IF 2.9 3区 医学 Q2 ONCOLOGY Pub Date : 2024-10-18 DOI: 10.1016/j.clbc.2024.10.012
Kadri Altundag
{"title":"Assessing and Comparing the Diagnostic Effectiveness of [<sup>18</sup>F]FDG PET/CT and [<sup>18</sup>F]FDG PET/MRI for Distant Metastases in Breast Cancer Patients With Invasive Lobular Carcinoma Histology: An Ongoing Topic of Debate?","authors":"Kadri Altundag","doi":"10.1016/j.clbc.2024.10.012","DOIUrl":"https://doi.org/10.1016/j.clbc.2024.10.012","url":null,"abstract":"","PeriodicalId":10197,"journal":{"name":"Clinical breast cancer","volume":" ","pages":""},"PeriodicalIF":2.9,"publicationDate":"2024-10-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142615804","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Local Recurrence and Survival Outcomes of Multifocal/Multicentric Breast Cancer After Breast Conserving Therapy: A systematic Review and Meta-Analysis. 多灶/多中心乳腺癌保乳治疗后的局部复发和生存结果:系统综述与元分析》。
IF 2.9 3区 医学 Q2 ONCOLOGY Pub Date : 2024-10-18 DOI: 10.1016/j.clbc.2024.10.009
Youshi Sun, Lu Gao, Xingtong Zhou, Zihao Wang, Yan Li, Qiang Sun

Background: The appropriateness of BCT for MF/MCBC is debated, with concerns about higher recurrence rates. This study aims to provide an updated systematic review and meta-analysis of LR and survival outcomes for MF/MCBC patients undergoing BCT.

Methods: PubMed, Web of Science, Embase, and the Cochrane Library were searched up to May 2024. Eligible studies included original research articles comparing LR, DFS, or OS in patients with MF/MC or UF breast cancer undergoing BCT or mastectomy. Meta-analyses for LR were conducted using the Mantel-Haenszel method. Published Kaplan-Meier curves for DFS and OS were digitized and aggregated to estimate summary survival curves.

Results: 21 studies were included in the meta-analysis for LR, comprising 28,589 participants, and 7 studies for survival analysis. The meta-analysis revealed that MF/MC breast cancer patients undergoing BCT had a significantly higher LR rate compared to UF patients (OR = 1.76, 95% CI: 1.24-2.49, P = .002), though recent studies indicated comparable LR rates. No significant difference in LR was found between MF/MC patients treated with BCT versus mastectomy (OR = 1.72, 95% CI: 0.96-3.10, P = .07). The estimated 3-, 5-, and 8-year DFS rates were 92.4%, 88.3%, and 84.5%, respectively, while the OS rates were 98.0%, 95.8%, and 91.8%.

Conclusion: BCT for MF/MC breast cancer was associated with higher LR rates compared to UF breast cancer, but the disparity was reducing in recent years. BCT offers comparable LR outcomes to mastectomy in MF/MC patients. Survival outcomes for MF/MC patients treated with BCT were favorable, affirming its oncological safety.

背景:MF/MCBC是否适合接受BCT治疗尚存争议,人们担心复发率会更高。本研究旨在对接受 BCT 的 MF/MCBC 患者的 LR 和生存结果进行最新的系统回顾和荟萃分析:方法:检索了截至 2024 年 5 月的 PubMed、Web of Science、Embase 和 Cochrane Library。符合条件的研究包括比较接受 BCT 或乳房切除术的 MF/MC 或 UF 乳腺癌患者的 LR、DFS 或 OS 的原始研究文章。采用 Mantel-Haenszel 方法对 LR 进行元分析。对已发表的DFS和OS的Kaplan-Meier曲线进行数字化处理并汇总,以估算出汇总生存曲线。结果:21项研究纳入了LR的荟萃分析,包括28589名参与者,7项研究纳入了生存分析。荟萃分析显示,与UF患者相比,接受BCT治疗的MF/MC乳腺癌患者的LR率明显更高(OR = 1.76,95% CI:1.24-2.49,P = .002),尽管最近的研究显示LR率相当。采用 BCT 与乳房切除术治疗的 MF/MC 患者的 LR 无明显差异(OR = 1.72,95% CI:0.96-3.10,P = .07)。估计3年、5年和8年的DFS率分别为92.4%、88.3%和84.5%,而OS率分别为98.0%、95.8%和91.8%:结论:与UF乳腺癌相比,BCT治疗MF/MC乳腺癌的LR率较高,但近年来这种差异正在缩小。BCT对MF/MC患者的LR结果与乳房切除术相当。接受BCT治疗的MF/MC患者的生存率良好,证实了其肿瘤安全性。
{"title":"Local Recurrence and Survival Outcomes of Multifocal/Multicentric Breast Cancer After Breast Conserving Therapy: A systematic Review and Meta-Analysis.","authors":"Youshi Sun, Lu Gao, Xingtong Zhou, Zihao Wang, Yan Li, Qiang Sun","doi":"10.1016/j.clbc.2024.10.009","DOIUrl":"https://doi.org/10.1016/j.clbc.2024.10.009","url":null,"abstract":"<p><strong>Background: </strong>The appropriateness of BCT for MF/MCBC is debated, with concerns about higher recurrence rates. This study aims to provide an updated systematic review and meta-analysis of LR and survival outcomes for MF/MCBC patients undergoing BCT.</p><p><strong>Methods: </strong>PubMed, Web of Science, Embase, and the Cochrane Library were searched up to May 2024. Eligible studies included original research articles comparing LR, DFS, or OS in patients with MF/MC or UF breast cancer undergoing BCT or mastectomy. Meta-analyses for LR were conducted using the Mantel-Haenszel method. Published Kaplan-Meier curves for DFS and OS were digitized and aggregated to estimate summary survival curves.</p><p><strong>Results: </strong>21 studies were included in the meta-analysis for LR, comprising 28,589 participants, and 7 studies for survival analysis. The meta-analysis revealed that MF/MC breast cancer patients undergoing BCT had a significantly higher LR rate compared to UF patients (OR = 1.76, 95% CI: 1.24-2.49, P = .002), though recent studies indicated comparable LR rates. No significant difference in LR was found between MF/MC patients treated with BCT versus mastectomy (OR = 1.72, 95% CI: 0.96-3.10, P = .07). The estimated 3-, 5-, and 8-year DFS rates were 92.4%, 88.3%, and 84.5%, respectively, while the OS rates were 98.0%, 95.8%, and 91.8%.</p><p><strong>Conclusion: </strong>BCT for MF/MC breast cancer was associated with higher LR rates compared to UF breast cancer, but the disparity was reducing in recent years. BCT offers comparable LR outcomes to mastectomy in MF/MC patients. Survival outcomes for MF/MC patients treated with BCT were favorable, affirming its oncological safety.</p>","PeriodicalId":10197,"journal":{"name":"Clinical breast cancer","volume":" ","pages":""},"PeriodicalIF":2.9,"publicationDate":"2024-10-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142615819","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Clinical breast cancer
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1